Commitments and Contingencies (Detail)													1 Months Ended			3 Months Ended	12 Months Ended
	Mar. 07, 2022 purportedStockholder	Mar. 05, 2022 case	Feb. 28, 2022 case	May 27, 2021 patent document	Mar. 01, 2021	Apr. 16, 2020 deniedMotion	Sep. 11, 2019 purportedStockholder	Feb. 07, 2019 decision interPartesReview	Sep. 07, 2018 patent	Mar. 18, 2016 patent	Feb. 08, 2016 patent	Oct. 28, 2014 petition	Aug. 31, 2021 compendia-priceReportingService	Dec. 22, 2016 patent abbreviatedNewDrugApplication	Sep. 30, 2007 USD ($) qtr	Dec. 31, 2019 USD ($)	Dec. 31, 2021 USD ($)	Feb. 03, 2022 USD ($)
BUNAVAIL
Contingencies And Commitments [Line Items]
Petitions filed | petition												3
Maximum petitions | petition												4
Number of decisions on remand purporting | decision								3
Number of previously instituted inter partes review | interPartesReview								3
BELBUCA
Contingencies And Commitments [Line Items]
Number of motions denied | deniedMotion						2
Teva Pharmaceuticals USA
Contingencies And Commitments [Line Items]
Number of invalid patents | patent											3			2
Number of patents allegedly infringed upon | patent										3
Number of abbreviated new drug applications (ANDA) | abbreviatedNewDrugApplication														3
Alvogen
Contingencies And Commitments [Line Items]
Number of patent invalidity defenses | patent				3					3
Bench trial period (in days)					3 days
Number of documents | document				2
Number of price reporting services offered | compendia-priceReportingService													5
Drachman v. BioDelivery Sciences International, Inc.
Contingencies And Commitments [Line Items]
Number of purported stockholders | purportedStockholder							2
Original term of directors (in years)							1 year
Current term of directors (in years)							3 years
Merger Litigation | Subsequent Event
Contingencies And Commitments [Line Items]
Number of purported stockholders | purportedStockholder	3
Number of cases filed by purported shareholders | case		2	2
Bankruptcy Matter | Subsequent Event
Contingencies And Commitments [Line Items]
Expected loss on recovery of preferential payments																		$ 45,186.9
CDC
Contingencies And Commitments [Line Items]
Royalties received															$ 20,000.00
Granted royalty on sales of the next BEMA product percentage															1.00%
Net sales of next BEMA Product															$ 7,500,000
Royalty expense payment period (in consecutive quarters) | qtr															3
Minimum | CDC
Contingencies And Commitments [Line Items]
Royalties received																	$ 375,000
Opioid PMR Consortium
Contingencies And Commitments [Line Items]
Participation expense																$ 4,300,000